Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: A report from the SPORTIF III and V trials

European Journal of Heart Failure

Volumn 9, Issue 6-7, 2007, Pages 730-739

  Cleland, John G F ^a   Shelton, Rhiddian ^a   Nikitin, Nikolay ^a   Ford, Sarah ^a   Frison, Lars ^b   Grind, Margaretha ^b  

^a Department of Cardiology ^*  (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Anticoagulants; Atrial fibrillation; Heart failure; Warfarin; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; WARFARIN; XIMELAGATRAN;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SURVIVAL RATE; THROMBOEMBOLISM; WARFARIN;

EID: 34247850845     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.01.013     Document Type: Article

References (27)

1. Khand A.U., Rankin A.C., Kaye G.C., and Cleland J.G. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 21 (2000) 614-632
2. Vasan R.S., and Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 101 (2000) 2118-2121
3. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 19 (1998) 990-1003
4. McMurray J., Ostergren J., Pfeffer M., et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur J Heart Fail 5 (2003) 261-270
5. Curtis A.B., Gersh B.J., Corley S.D., et al. Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 149 (2005) 645-649
6. Swedberg K., Olsson L.G., Charlesworth A., et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J 26 (2005) 1303-1308
7. DiMarco J.P., Flaker G., Waldo A.L., et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 149 (2005) 650-656
8. Witte K.K., Desilva R., Chattopadhyay S., Ghosh J., Cleland J.G., and Clark A.L. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J 147 (2004) 924-930
9. Olsson S.B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362 (2003) 1691-1698
10. Halperin J.L. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 146 (2003) 431-438
11. Albers G.W., Diener H.C., Frison L., et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293 (2005) 690-698
12. Diener H.C. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 21 (2006) 279-293
13. Khand A.U., Cleland J.G., and Deedwania P.C. Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev 7 (2002) 267-283
14. van Walraven C., Hart R.G., Singer D.E., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288 (2002) 2441-2448
15. Lip G.Y., and Gibbs C.R. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 33 (1999) 1424-1426
16. Cleland J.G. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol 12 (1997) 276-287
17. Cleland J.G., Massie B.M., and Packer M. Sudden death in heart failure: vascular or electrical?. Eur J Heart Fail 1 (1999) 41-45
18. Horwich T.B., Patel J., MacLellan W.R., and Fonarow G.C. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108 (2003) 833-838
19. Orn S., Cleland J.G., Romo M., Kjekshus J., and Dickstein K. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. Am J Med 118 (2005) 752-758
20. Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 102 (2000) 611-616
21. Petersen P., Boysen G., Godtfredsen J., Andersen E.D., and Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1 (1989) 175-179
22. Shelton R.J., Clark A.L., Goode K., Rigby A.S., and Cleland J.G. The diagnostic utility of N-Terminal pro-B-type Natriuretic for the detection of major strucural heart desease in patients with atrial fibrillation. Eur Heart J 27 19 (2006) 2353-2361
23. Cooper H.A., Dries D.L., Davis C.E., Shen Y.L., and Domanski M.J. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100 (1999) 1311-1315
24. Cleland J.G., Ghosh J., Freemantle N., et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6 (2004) 501-508
25. Cleland J.G., Findlay I., Jafri S., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 148 (2004) 157-164
26. Cleland J.G. Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 44 (2002) 275-292
27. Cleland J.G., Bulpitt C.J., Falk R.H., et al. Is aspirin safe for patients with heart failure?. Br Heart J 74 (1995) 215-219